0IMT.L
Photocure ASA [0IMT.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0IMT.L Stock Summary
In the News
0IMT.L Financial details
Company Rating
-
Market Cap
1.56B
Income
267K
Revenue
500.66M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
87
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-55.97
Forward P/E
-
PEG
5.58
P/S
0.03
P/B
4.02
P/C
-
P/FCF
0.6
Quick Ratio
3.89
Current Ratio
4.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-100.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-63.17%
Revenue last 5Y
12.2%
Revenue Q/Q
32.54%
EPS Q/Q
-355.56%
-
-
-
-
SMA20
-2.64%
SMA50
-14.78%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-7%
ROC
-0.03%
Gross Margin
94%
Oper. Margin
-4%
Profit Margin
-7%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
40.85-71.9
52W High
-24.08%
52W Low
+34.75%
RSI
49.94
Rel Volume
2.61
Avg Volume
2.78K
Volume
7.25K
Perf Week
-4.09%
Perf Month
-8.64%
Perf Quarter
-
Perf Half Y
4.66%
-
-
-
-
Beta
0.893
-
-
Volatility
2.31%, 2.89%
Prev Close
-0.74%
Price
53.9
Change
-2%
Company Profile
- Volume Average 2.78K
- Market Capitalization 1.56B
- Employee 87
- CEO Mr. Daniel Schneider
- Headquarters Oslo,NO
- IPO Date 2011-01-14
-
Website
https://www.photocure.com 
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
